Targets › IFNG
15 programs from 14 companies in 15 trials: 10 Phase 2, 3 Phase 1, 2 Phase 3; Oncology, Infectious disease, Hematology; next expected readout Nov 2026.
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. (UniProt, P01579)
Open in Phaseline: the race on IFNG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospices Civils de Lyon | Interferon gamma Interferon gamma immunostimulatory cytokine | IFNG | Phase 3 | Pneumonia, Ventilator-Associated | Jul 2027 |
| University Hospital, Limoges | Interferon Gamma 1-b Interferon gamma cytokine for immune restoration in ICU-acquired immunosuppression | IFNG | Phase 3 | Sustained Immunosuppression | Oct 2028 |
| Hellenic Institute for the Study of Sepsis | Emapalumab-Izsg Monoclonal antibody blocking interferon-gamma (IFNγ) | IFNG | Phase 2 | Sepsis | Nov 2026 |
| Joseph Oved | Emapalumab Interferon gamma inhibitor | IFNG | Phase 2 | Primary Immune Regulatory Disorder | Mar 2027 |
| University of Miami | Emapalumab Interferon gamma inhibitor | IFNG | Phase 2 | Dermatomyositis | Jul 2027 |
| Marcela V. Maus, M.D.,Ph.D. | Emapalumab Interferon gamma inhibitor | IFNG | Phase 2 | Large B-cell Lymphoma | Aug 2027 |
| Hefei Cancer Hospital of the Chinese Academy of Sciences | Interferon-γ Type II interferon cytokine | IFNG | Phase 2 | Locally Advanced Esophageal Squamous Cell Carcinoma | Mar 2028 |
| M.D. Anderson Cancer Center | Emapalumab Interferon gamma inhibitor | IFNG | Phase 2 | Cytopenia | Aug 2028 |
| Assistance Publique - Hôpitaux de Paris | Interferon Gamma 1-b Interferon gamma-1b, recombinant interferon gamma therapy | IFNG | Phase 2 | Post-aggressive Immunosuppression | Mar 2029 |
| Stamford Pharmaceuticals | SP-002 Replication deficient adenovirus-5 encoding human interferon gamma (IFNγ) | IFNG | Phase 2 | Basal Cell Carcinoma | Mar 2029 |
| Memorial Sloan Kettering Cancer Center | Emapalumab Interferon gamma inhibitor | IFNG | Phase 2 | Aplastic Anemia | May 2029 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Emapalumab Interferon gamma inhibitor | IFNG | Phase 2 | Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis | Mar 2031 |
| City of Hope Medical Center | Emapalumab Interferon gamma inhibitor | IFNG | Phase 1 | Acute Myeloid Leukemia | May 2027 |
| Nerissa T. Viola | [89Zr]Zr-DFO-emapalumab Interferon-gamma (IFN-γ) PET imaging agent - radiolabeled anti-IFN-γ antibody | IFNG | Phase 1 | Non Small Cell Lung Cancer | Jun 2028 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Emapalumab-Izsg Interferon gamma blocking antibody | IFNG | Phase 1 | Chronic Granulomatous Disease | Dec 2032 |
Acute Myeloid Leukemia (1) Aplastic Anemia (1) Cytopenia (1) Locally Advanced Esophageal Squamous Cell Carcinoma (1) Large B-cell Lymphoma (1) Basal Cell Carcinoma (1) Post-aggressive Immunosuppression (1) Chronic Granulomatous Disease (1) Pneumonia, Ventilator-Associated (1) Dermatomyositis (1) Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis (1) Primary Immune Regulatory Disorder (1)
antibody (6), mixed (5), protein or peptide (3), small molecule (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) City of Hope Medical Center (1) Memorial Sloan Kettering Cancer Center (1) M.D. Anderson Cancer Center (1) Hefei Cancer Hospital of the Chinese Academy of Sciences (1) Marcela V. Maus, M.D.,Ph.D. (1) Stamford Pharmaceuticals (1) Assistance Publique - Hôpitaux de Paris (1) Hospices Civils de Lyon (1) University of Miami (1) Joseph Oved (1) University Hospital, Limoges (1) Nerissa T. Viola (1) Hellenic Institute for the Study of Sepsis (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.